How to Change Ceruloplasmin Levels in Heart Disease?

Year 2018, Volume: 21 Issue: 1, 61 - 64, 01.04.2018

Hatice Sezen Yusuf Sezen

Abstract

Ceruloplasmin
(CP) is a blue serum protein found in human serum; it carries approximately 95%
of the total circulating copper (Cu) in healthy individuals. The relationship
of CP with OS, inflammation, and DNA damage is known. Oxidative stress (OS),
inflammation, and DNA damage are the main causes underlying atherosclerotic
heart disease. Several studies have indicated a close association between high
serum CP and several types of heart disease. However, the CP levels are still unknown
in many heart diseases. To gather the studies of CP in heart disease and to
prepare the ground for new studies for researchers, we designed this review.

Keywords

Ceruloplasmin, oxidative stress, heart disease

Kalp Hastalıklarında Seruloplazmin Değerleri Nasıl Değişir?

Abstract

Kanda
yaygın olarak bulunan ve mavi protein olarak adlandırılan seruloplazmin (CP)
sağlıklı kişilerde kanda bakırın %95’ini taşır. Oksidatif stres, inflamasyon ve
DNA hasarı ile ilişkisinin varlığı bilinmektedir. Oksidatif stres, inflamasyon
ve DNA hasarı, başta koroner arter hastalığı olmak üzere pek çok kalp hastalığı
etyolojisinde de suçlanmaktadır. Çok sayıda çalışma kalp hastalıklarında CP’nin
yerini ortaya koymuştur. Ancak çoğu kalp hastalığında halen CP seviyelerinin
nasıl değiştiği bilinmemektedir. Literatürdeki CP ile yapılmış kalp
hastalıklarındaki çalışmaları bir araya getirmek ve yapılacak yeni çalışmalara
zemin hazırlamak için bu derlemeyi yaptık.

Keywords

Seruloplazmin, oksidatif stres, kalp hastalıkları

References

• 1. Ryden L. Copper protein and copper enzymes. In: Lontie L (ed). Florida: CRC Press, Boca Raton, 1984:37-108.
• 2. Fox PL, Mukhopadhyay C, Ehrenwald E. Structure, oxidant activity, and cardiovascular mechanisms of human ceruloplasmin. Life Sci 1995;56:1749-58.
• 3. Fox PL, Mazumder B, Ehrenwald E, Mukhopadhyay CK. Ceruloplasmin and cardiovascular disease. Free Radic Biol Med 2000;28:1735-44.
• 4. Holmberg CG, Laurell CB. Histaminolytic activity of a copper protein in serum. Nature 194814;161:236.
• 5. Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol 1990;186:1-85.
• 6. http://www.who.int/mediacentre/factsheets/fs310/en/
• 7. Chistiakov DA, Orekhov AN, Bobryshev YV. Endothelial barrier and its abnormalities in cardiovascular disease. Front Physiol 2015;6:365.
• 8. Lubrano V, Balzan S. Enzymatic antioxidant system in vascular inflammation and coronary artery disease. World J Exp Med 2015;5:218-24.
• 9. Bhat MA, Mahajan N, Gandhi G. DNA and chromosomal damage in coronary artery disease patients. EXCLI J 2013;12:872-84.
• 10. Vasilyev VB. Interactions of caeruloplasmin with other proteins participating in inflammation. Biochem Soc Trans 2010;38:947-51.
• 11. Uriu-Adams JY, Keen CL. Copper, oxidative stress, and human health. Mol Aspects Med 2005;26:268-98.
• 12. Kim RH, Park JE, Park JW. Ceruloplasmin enhances DNA damage induced by hydrogen peroxide in vitro. Free Radic Res 2000;33:81-9.
• 13. Bustamante JB, Mateo MC, Fernandez J, de Quiros B, Manchado OO. Zinc, copper and ceruloplasmin in arteriosclerosis. Biomedicine 1976;25:244-5.
• 14. Powell JT, Muller BR, Greenhalgh RM. Acute phase proteins in patients with abdominal aortic aneurysms. J Cardiovasc Surg (Torino) 1987;28:528-30.
• 15. Jayakumari N, Ambikakumari V, Balakrishnan KG, Iyer KS. Antioxidant status in relation to free radical production during stable and unstable anginal syndromes. Atherosclerosis 1992;94:183-90.
• 16. Belch JJ, Chopra M, Hutchison S, Lorimer R, Sturrock RD, Forbes CD, et al. Free radical pathology in chronic arterial disease. Free Radic Biol Med 1989;6:375-8.
• 17. Fortna RR, Watson HA, Nyquist SE. Glycosyl phosphatidylinositol-anchored ceruloplasmin is expressed by rat Sertoli cells and is concentrated in detergent-insoluble membrane fractions. Biol Reprod 1999;61:1042-9.
• 18. Floris G, Medda R, Padiglia A, Musci G. The physiopathological significance of ceruloplasmin. A possible therapeutic approach. Biochem Pharmacol 2000;60:1735-41.
• 19. Harris ED. A requirement for copper in angiogenesis. Nutr Rev 2004;62:60-4.
• 20. Hannan GN, McAuslan BR. Modulation of synthesis of specific proteins in endothelial cells by copper, cadmium, and disulfiram: an early response to an angiogenic inducer of cell migration. J Cell Physiol 1982;111:207-12.
• 21. Klebanoff SJ. Bactericidal effect of Fe2+, ceruloplasmin, and phosphate. Arch Biochem Biophys 1992;295:302-8.
• 22. Kok FJ, Van Duijn CM, Hofman A, Van der Voet GB, De Wolff FA, Paays CH, et al. Serum copper and zinc and the risk of death from cancer and cardiovascular disease. Am J Epidemiol 1988;128:352-9.
• 23. Salonen JT, Salonen R, Korpela H, Suntioinen S, Tuomilehto J. Serum copper and the risk of acute myocardial infarction: a prospective population study in men in eastern Finland. Am J Epidemiol 1991;134:268-76.
• 24. Reunanen A, Knekt P, Aaran RK. Serum ceruloplasmin level and the risk of myocardial infarction and stroke. Am J Epidemiol 1992;136:1082-90.
• 25. Tang WH, Wu Y, Hartiala J, Fan Y, Stewart AF, Roberts R, et al. Clinical and genetic association of serum ceruloplasmin with cardiovascular risk. Arterioscler Thromb Vasc Biol 2012;32:516-22.
• 26. Frieden E, Hsieh HS. The biological role of ceruloplasmin and its oxidase activity. Adv Exp Med Biol 1976;74:505-29.
• 27. Gurdol F, Ademoglu E. Biyokimya. 3. baskı. İstanbul: Nobel Tıp Kitapevleri, 2014:483-4.
• 28. Onat T, Kaya E, Sözmen EY. İnsan biyokimyası. 2. baskı. Ankara: Palme Yayıncılık, 2005:376-7.
• 29. Cabassi A, Binno SM, Tedeschi S, Ruzicka V, Dancelli S, Rocco R, et al. Low serum ferroxidase I activity is associated with mortality in heart failure and related to both peroxynitrite-induced cysteine oxidation and tyrosine nitration of ceruloplasmin. Circ Res 2014;114:1723-32.
• 30. Hammadah M, Fan Y, Wu Y, Hazen SL, Tang WH. Prognostic value of elevated serum ceruloplasmin levels in patients with heart failure. J Card Fail 2014;20:946-52.
• 31. Dadu RT, Dodge R, Nambi V, Virani SS, Hoogeveen RC, Smith NL, et al. Ceruloplasmin and heart failure in the atherosclerosis risk in communities study. Circ Heart Fail 2013;6:936-43.
• 32. Engström G, Hedblad B, Tydén P, Lindgärde F. Inflammation-sensitive plasma proteins are associated with increased incidence of heart failure: a population-based cohort study. Atherosclerosis 2009;202:617-22.
• 33. Karaye KM, Yahaya IA, Lindmark K, Henein MY. Serum selenium and ceruloplasmin in nigerians with peripartum cardiomyopathy. Int J Mol Sci 2015;16:7644-54.
• 34. Xu Y, Lin H, Zhou Y, Cheng G, Xu G. Ceruloplasmin and the extent of heart failure in ischemic and nonischemic cardiomyopathy patients. Mediators Inflamm 2013:348145.
• 35. Sampietro T, Neglia D, Bionda A, Dal Pino B, Bigazzi F, Puntoni M, et al. Inflammatory markers and serum lipids in idiopathic dilated cardiomyopathy. Am J Cardiol 2005;96:1718-20.
• 36. Hendrichová M, Málek F, Kopřivová H, Vránová J, Ošťádal P, Krátká K, et al. Correlation of NT-proBNP with metabolic liver function as assessed with (13)C-methacetin breath test in patients with acute decompensated heart failure. Int J Cardiol 2010;144:321-2.
• 37. Kaya Z, Kaya BC, Sezen H, Bilinc H, Asoglu R, Yıldız A, et al. Serum ceruloplasmin levels in acute decompensated heart failure. Clin Ter 2013;164:e187-91.
• 38. Mateescu MA, Chahine R, Roger S, Atanasiu R, Yamaguchi N, Lalumiere G, et al. Protection of myocardial tissue against deleterious effects of oxygen free radicals by ceruloplasmin. Arzneimittel-Forschung 1995;45:476-80.
• 39. Chahine R, Mateescu MA, Roger S, Yamaguchi N, de Champlain J, Nadeau R. Protective effects of ceruloplasmin against electrolysis-induced oxygen free radicals in rat heart. Can J Physiol and Pharmacol 1991;69:1459-64.
• 40. Shishehbor MH, Aviles RJ, Brennan ML, Fu X, Goormastic M, Pearce GL, et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 2003;289:1675-80.
• 41. Parastatidis I, Thomson L, Fries DM, Moore RE, Tohyama J, Fu X, et al. Increased protein nitration burden in the atherosclerotic lesions and plasma of apolipoprotein a-i deficient mice. Circulation Research 2007;101:368-76.
• 42. Thomson L, Tenopoulou M, Lightfoot R, Tsika E, Parastatidis I, Martinez M, et al. Immunoglobulins against tyrosine-nitrated epitopes in coronary artery disease. Circulation 2012;126:2392-401.
• 43. Shiva S, Wang X, Ringwood LA, Xu X, Yuditskaya S, Annavajjhala V, et al. Ceruloplasmin is a NO oxidase and nitrite synthase that determines endocrine NO homeostasis. Nat Chem Biol 2006; 2:486-93.
• 44. Zhang PY, Xu X, Li XC. Cardiovascular diseases: oxidative damage and antioxidant protection. Eur Rev Med Pharmacol Sci 2014;18:3091-6.
• 45. Hua S, Song C, Geczy CL, Freedman SB, Witting PK. A role for acute-phase serum amyloid A and high-density lipoprotein in oxidative stress, endothelial dysfunction and atherosclerosis. Redox Rep 2009;14:187-96.
• 46. Said HM, Redha R. A carrier-mediated transport for folate in basolateral membrane vesicles of rat small intestine. Biochem J 1987;247:141-6.
• 47. Göçmen AY, Sahin E, Semiz E, Gümuşlü S. Is elevated serum ceruloplasmin level associated with increased risk of coronary artery disease? Can J Cardiol 2008;24:209-12.
• 48. Suciu A, Chirulescu Z, Zeana C, Pîrvulescu R. Study of serum ceruloplasmin and of the copper/zinc ratio in cardiovascular diseases. Rom J Internal Med 1992;30:193-200.
• 49. Brunetti ND, Correale M, Pellegrino PL, Cuculo A, Biase MD. Acute phase proteins in patients with acute coronary syndrome: correlations with diagnosis, clinical features, and angiographic findings. Eur J Intern Med 2007;18:109-17.
• 50. Brunetti ND, Pellegrino PL, Correale M, De Gennaro L, Cuculo A, Di Biase M. Acute phase proteins and systolic dysfunction in subjects with acute myocardial infarction. J Thromb Thrombolysis 2008 26:196-202.
• 51. Grammer TB, Kleber ME, Silbernagel G, Pilz S, Scharnagl H, Lerchbaum E, et al. Copper, ceruloplasmin, and long-term cardiovascular and total mortality (the Ludwigshafen Risk and Cardiovascular Health Study). Free Radic Res 2014;48:706-15.
• 52. Singh TK. Serum ceruloplasmin in acute myocardial infarction. Acta Cardiologica 1992;47:321-9.
• 53. Kennedy DJ, Fan Y, Wu Y, Pepoy M, Hazen SL, Tang WH. Plasma ceruloplasmin, a regulator of nitric oxide activity, and incident cardiovascular risk in patients with CKD. Clin J Am Soc Nephrol 2014;9:462-7.
• 54. Korochkin IM, Orlova NV, Aleshkin VA, Berkinbaev SF, Chukaeva II. Clinical and prognostic value of monitoring the acute phase protein levels in patients with myocardial infarction. Kardiologiia 1990;30:20-3.
• 55. Kaur K, Bedi G, Kaur M, Vij A, Kaur I. Lipid peroxidation and the levels of antioxidant enzymes in coronary artery disease. Indian J Clin Biochem 2008;23:33-7.
• 56. Adamsson Eryd S, Sjögren M, Smith JG, Nilsson PM, Melander O, Hedblad B, et al. Ceruloplasmin and atrial fibrillation: evidence of causality from a population-based mendelian randomization study. J Intern Med 2014;275:164-71.
• 57. Adamsson Eryd S, Smith JG, Melander O, Hedblad B, Engström G. Inflammation-sensitive proteins and risk of atrial fibrillation: a population-based cohort study. Eur J Epidemiol 2011;26:449-55.
• 58. Atanasiu R, Dumoulin MJ, Chahine R, Mateescu MA, Nadeau R. Antiarrhythmic effects of ceruloplasmin during reperfusion in the ischemic isolated rat heart. Can J Physiol Pharmacol 1995;73:1253-61.
• 59. Shanidze E, Zhvania M. Activity of lipid peroxidation processes and the condition of antioxidative defense system in children with rheumatic fever. Georgian Med News 2005;127:38-40.
• 60. Polizopoulou ZS, Koutinas CK, Cerón JJ, Tvarijonaviciute A, Martínez-Subiela S, Dasopoulou A, et al. Correlation of serum cardiac troponin I and acute phase protein concentrations with clinical staging in dogs with degenerative mitral valve disease. Vet Clin Pathol 2015;44:397-404.
• 61. Petelenz T, Drózdz M, Słomińska-Petelenz T, Jendryczko A, Kucharz E, Drazkiewicz U, et al. Investigations upon collagen metabolites in blood serum and urine of patients with acquired valvular heart disease. Mater Med Pol 1989;21:199-205.
• 62. Buyukhatıpoglu H, Sezen Y, Yildiz A, Guntekin U, Bas M, Polat M, et al. Effects of statin use on total oxidant and antoxidant capacity and ceruloplasmin activity. Clin Invest Med 2010;33:E313-E20.
• 63. Vasconcelos SM, Goulart MO, Silva MA, Manfredini V, Benfato Mda S, Rabelo LA, et al. Markers of redox imbalance in the blood of hypertensive patients of a community in Northeastern Brazil. Arq Bras Cardiol 2011;97:141-7.